Matches in Nanopublications for { ?s ?p "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.
- NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290213.RAgGuWKELWvMdZ37NdklaVxzitgMa7WU9DOv6Pyjo7_VM130_provenance.
- NP1290214.RAEglDqDMEsMiumOkbx7fWkH_w-FLRuU6AMqB2cMywxhI130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290214.RAEglDqDMEsMiumOkbx7fWkH_w-FLRuU6AMqB2cMywxhI130_provenance.
- NP1290215.RA3JvkeOg0d780Sem2aAlg0yM3faLoVfxZQMV1j7sP7to130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290215.RA3JvkeOg0d780Sem2aAlg0yM3faLoVfxZQMV1j7sP7to130_provenance.